TY - JOUR
T1 - Mathematical modeling of tumor growth and treatment
AU - Enderling, Heiko
AU - Chaplain, Mark A. J.
PY - 2014
Y1 - 2014
N2 - Using mathematical models to simulate dynamic biological processes has a long history. Over the past couple of decades or so, quantitative approaches have also made their way into cancer research. An increasing number of mathematical, physical, computational and engineering techniques have been applied to various aspects of tumor growth, with the ultimate goal of understanding the response of the cancer population to clinical intervention. So-called in silico trials that predict patient-specific response to various dose schedules or treatment combinations and sequencing are on the way to becoming an invaluable tool to optimize patient care. Herein we describe fundamentals of mathematical modeling of tumor growth and tumor-host interactions, and summarize some of the seminal and most prominent approaches.
AB - Using mathematical models to simulate dynamic biological processes has a long history. Over the past couple of decades or so, quantitative approaches have also made their way into cancer research. An increasing number of mathematical, physical, computational and engineering techniques have been applied to various aspects of tumor growth, with the ultimate goal of understanding the response of the cancer population to clinical intervention. So-called in silico trials that predict patient-specific response to various dose schedules or treatment combinations and sequencing are on the way to becoming an invaluable tool to optimize patient care. Herein we describe fundamentals of mathematical modeling of tumor growth and tumor-host interactions, and summarize some of the seminal and most prominent approaches.
UR - http://www.scopus.com/inward/record.url?scp=84906217098&partnerID=8YFLogxK
U2 - 10.2174/1381612819666131125150434
DO - 10.2174/1381612819666131125150434
M3 - Article
AN - SCOPUS:84906217098
SN - 1381-6128
VL - 20
SP - 4934
EP - 4940
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 30
ER -